Fabrice Egros has sold SNDX and made no open-market buys since Mar 2021

Egros Fabrice is a Person and a pharmaceutical executive with experience in corporate development, strategy, business development, and board leadership. He currently serves as President of Global Corporate Development & Strategy at Lupin, where he drives acquisition, licensing, and growth-market strategy across Latin America and Asia Pacific; Lupin notes that he has also held regional and global roles at UCB, Sanofi, and Pfizer.(

Fabrice Egros also served as a Director and board member of Syndax Pharmaceuticals, with SEC filings identifying him as a director in 2020 and a company filing noting his resignation effective February 22, 2022.( His professional profile lists prior responsibility for strategic alternatives, partnership support, and audit committee service at Syndax, and it also indicates education that includes a PharmD, a Ph.D. in clinical pharmacology from Université Paris-Saclay, and a general management program at Harvard Business School.(

Written by Perplexity from public sources.